U.S. markets open in 8 hours 54 minutes

Aptorum Group Limited (APM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.3200-0.0300 (-2.22%)
At close: 04:00PM EST

Aptorum Group Limited

17 Hanover Square
London W1S 1BN
United Kingdom
44 20 8092 9299

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Chung Yuen HuenFounder, Chairman & CEO474.53kN/A1980
Mr. Darren LuiPres & Exec. Director256.54kN/A1981
Ms. Sabrina KhanCFO & Company Sec.372.54kN/A1982
Dr. Clark ChengChief Medical Officer & Exec. Director465.26kN/A1980
Dr. Wai Yip LeeHead of R&D405.2kN/A1974
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.

Corporate Governance

Aptorum Group Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.